Literature DB >> 23213177

Evidence of associations of APOBEC3B gene deletion with susceptibility to persistent HBV infection and hepatocellular carcinoma.

Tongwen Zhang1, Jianqiang Cai, Jiang Chang, Dianke Yu, Chen Wu, Tao Yan, Kan Zhai, Xinyu Bi, Hong Zhao, Jian Xu, Wen Tan, Chunfeng Qu, Dongxin Lin.   

Abstract

APOBEC3s are a family of cytidine deaminases involved in innate cellular immunity against virus including hepatitis B virus (HBV). A germline deletion across APOBEC3A and APOBEC3B (A3B) genes results in complete removal of the A3B coding region and destroys A3B expression. To determine whether this deletion affects susceptibility to HBV infection and HBV-related hepatocellular carcinoma (HCC), A3B genotypes were analyzed in 1124 individuals with HCC, 510 individuals with persistent HBV infection and 826 healthy controls and the association was estimated by odds ratio (OR) and 95% confidence interval (CI) computed by logistic regression. We also examined the effects of A3B on HBV genome hypermutation and replication in HCC cells. We observed a significantly higher frequency of the A3B deletion allele in persistent HBV carriers (33.3%; P = 0.0015) and HCC patients (37.9%; P = 1.28 × 10(-11)) compared with that in controls (27.5%). An increased risk for persistent HBV infection (OR = 1.35, 95% CI: 1.03-1.77) and HCC development (OR = 1.90, 95% CI: 1.58-2.28) was associated with at least one A3B deletion allele (+/- or -/- genotype) compared with the +/+ genotype. Transfection of A3B in HepG2 cells caused a substantial reduction of HBV RNA levels and G → A hypermutation in the HBV genome. Interestingly, a cytidine deaminase null mutant of A3B (E255A) also inhibited HBV RNA production although it was unable to edit HBV. These results suggest that the deletion of A3B attenuates HBV clearance, which in turn may result in persistent HBV infection and increased risk for developing HCC. Further studies are needed to verify our findings.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23213177     DOI: 10.1093/hmg/dds513

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  31 in total

1.  Leveraging premalignant biology for immune-based cancer prevention.

Authors:  Avrum Spira; Mary L Disis; John T Schiller; Eduardo Vilar; Timothy R Rebbeck; Rafael Bejar; Trey Ideker; Janine Arts; Matthew B Yurgelun; Jill P Mesirov; Anjana Rao; Judy Garber; Elizabeth M Jaffee; Scott M Lippman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-16       Impact factor: 11.205

Review 2.  Hypermutation in human cancer genomes: footprints and mechanisms.

Authors:  Steven A Roberts; Dmitry A Gordenin
Journal:  Nat Rev Cancer       Date:  2014-12       Impact factor: 60.716

3.  Clustered and genome-wide transient mutagenesis in human cancers: Hypermutation without permanent mutators or loss of fitness.

Authors:  Steven A Roberts; Dmitry A Gordenin
Journal:  Bioessays       Date:  2014-02-26       Impact factor: 4.345

4.  A single non-synonymous NCOA5 variation in type 2 diabetic patients with hepatocellular carcinoma impairs the function of NCOA5 in cell cycle regulation.

Authors:  Xinhui Liu; Feiye Liu; Shenglan Gao; Jake Reske; Aimin Li; Chin-Lee Wu; Chengfeng Yang; Fengsheng Chen; Rongcheng Luo; Hua Xiao
Journal:  Cancer Lett       Date:  2017-01-27       Impact factor: 8.679

5.  Analysis of APOBEC3A/3B germline deletion polymorphism in breast, cervical and oral cancers from South India and its impact on miRNA regulation.

Authors:  Sundaramoorthy Revathidevi; Mayakannan Manikandan; Arunagiri Kuha Deva Magendhra Rao; Vilvanathan Vinothkumar; Ganesan Arunkumar; Kottayasamy Seenivasagam Rajkumar; Rajendran Ramani; Ramamurthy Rajaraman; Chandrasekar Ajay; Arasambattu Kannan Munirajan
Journal:  Tumour Biol       Date:  2016-05-07

6.  APOBEC mediated mutagenesis drives genomic heterogeneity in endometriosis.

Authors:  Sundaramoorthy Revathidevi; Hirofumi Nakaoka; Kazuaki Suda; Naoko Fujito; Arasambattu Kannan Munirajan; Kosuke Yoshihara; Takayuki Enomoto; Ituro Inoue
Journal:  J Hum Genet       Date:  2022-01-12       Impact factor: 3.172

7.  APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry.

Authors:  Dennis Xuan; Guoliang Li; Qiuyin Cai; Sandra Deming-Halverson; Martha J Shrubsole; Xiao-Ou Shu; Mark C Kelley; Wei Zheng; Jirong Long
Journal:  Carcinogenesis       Date:  2013-05-28       Impact factor: 4.944

8.  APOBEC3 deletion polymorphism is associated with epithelial ovarian cancer risk among Chinese women.

Authors:  Guannan Qi; Huijuan Xiong; Changju Zhou
Journal:  Tumour Biol       Date:  2014-02-28

Review 9.  An Evolutionary Perspective on the Impact of Genomic Copy Number Variation on Human Health.

Authors:  Marie Saitou; Omer Gokcumen
Journal:  J Mol Evol       Date:  2019-09-14       Impact factor: 2.395

10.  APOBEC3B deletion polymorphism and lung cancer risk in the southern Chinese population.

Authors:  Xiaosong Ben; Dan Tian; Jiayu Liang; Min Wu; Fan Xie; Jinlong Zheng; Jingmin Chen; Qiaoyuan Fei; Xinrong Guo; Xueqiong Weng; Shan Liu; Xin Xie; Yuting Ying; Guibin Qiao; Chunxia Jing
Journal:  Ann Transl Med       Date:  2021-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.